title: Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
abstract: CD6 is a cell surface receptor expressed on the majority of T cells and a subset of B cells. When expressed, CD6 contributes to lymphocyte activation through its extracellular domain 1, while adhesion and cellular migration are related to the extracellular scavenger receptor cysteine-rich domain (SRCR-D)-3 of CD6. Itolizumab, clone T1h, is a newly developed humanized IgG1 monoclonal antibody that targets CD6 SRCR-D1 and blocks immune activation. Itolizumab has been proposed to be effective in autoimmune diseases such as rheumatoid arthritis, Sjögren's syndrome and multiple sclerosis. In Sjögren's syndrome, the utilization of itolizumab as therapeutic option is reinforced by our recent observation that ALCAM, the CD6 ligand, is overexpressed and that CD6-positive T and B cells are detected within salivary glands from Sjögren's syndrome patients. In this study, itolizumab-positive target cells were characterized within both peripheral blood and salivary glands in order to provide rational for anti-CD6 treatment in Sjögren's syndrome.
authors.affiliation: EA 2216 Immunology and Pathology, Brest University Medical School, SFR ScinBios, University of Brittany, Brest, France.
authors.forename: Christelle
authors.initials: C
authors.lastname: Le Dantec
authors.forename: Ruby
authors.initials: R
authors.lastname: Alonso
authors.forename: Tinhinane
authors.initials: T
authors.lastname: Fali
authors.forename: Enrique
authors.initials: E
authors.lastname: Montero
authors.forename: Valérie
authors.initials: V
authors.lastname: Devauchelle
authors.forename: Alain
authors.initials: A
authors.lastname: Saraux
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Pers
authors.forename: Yves
authors.initials: Y
authors.lastname: Renaudineau
mesh_terms: D020410:Activated-Leukocyte Cell Adhesion Molecule / Q000235:genetics / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000235:genetics; D015703:Antigens, CD / Q000276:immunology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002448:Cell Adhesion / Q000235:genetics; D002465:Cell Movement / Q000235:genetics; D002469:Cell Separation; D005434:Flow Cytometry; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D015202:Protein Engineering; D017434:Protein Structure, Tertiary / Q000235:genetics; D051116:Receptors, Scavenger / Q000235:genetics; D012469:Salivary Glands / Q000473:pathology; D012859:Sjogren's Syndrome / Q000628:therapy*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
chemical_list: D020410:Activated-Leukocyte Cell Adhesion Molecule; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; C062279:CD6 antigen; D051116:Receptors, Scavenger